Clinical Trial

Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

Study acronym: IGNITE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase II, open-label, single-arm study of CD40/Dectin-1 immunotherapy as maintenance treatment in patients with unresectable pancreatic ductal adenocarcinoma (PDA) who have not progressed following 4-8 months of first line (1L) chemotherapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-22; most recent amendment 2026-06-08.
Status change: Not Yet Recruiting → Recruiting 2025-12-08
Trial Details
NCT Number NCT07199764
Lead Sponsor University of Pennsylvania
Collaborators: Lustgarten Foundation
Conditions Pancreatic Ductal Adenocarcinoma
Enrollment 100 participants
Start Date 2025-11-25
Primary Completion 2027-10 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-10